This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Jun 2011

Boehringer Ingelheim Signs Deal with Zealand

The agreement gives Boehringer Ingelheim global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate.

German pharmaceutical firm Boehringer Ingelheim has won global rights to Zealand Pharma’s diabetes and obesity treatments.

 

The agreement with Zealand Pharma gives Boehringer Ingelheim global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will conduct the first Phase I study with ZP2929, supported by research, development and commercialisation funding from Boehringer Ingelheim.

 

During the first two years of the collaboration, Zealand Pharma will receive milestone and other payments of up to €41m including research funding of €4m.

 

The two companies will fo

Related News